These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

400 related items for PubMed ID: 28369376

  • 1. Association of circulating tumour cells with early relapse and 18F-fluorodeoxyglucose positron emission tomography uptake in resected non-small-cell lung cancers.
    Bayarri-Lara CI, de Miguel Pérez D, Cueto Ladrón de Guevara A, Rodriguez Fernández A, Puche JL, Sánchez-Palencia Ramos A, Ruiz Zafra J, Giraldo Ospina CF, Delgado-Rodríguez M, Expósito Ruiz M, Moyano Rodriguez MJ, Lorente JA, Serrano MJ.
    Eur J Cardiothorac Surg; 2017 Jul 01; 52(1):55-62. PubMed ID: 28369376
    [Abstract] [Full Text] [Related]

  • 2. Correlations between circulating tumor cell phenotyping and 18F-fluorodeoxyglucose positron emission tomography uptake in non-small cell lung cancer.
    Bian J, Yan K, Liu N, Xu X.
    J Cancer Res Clin Oncol; 2020 Oct 01; 146(10):2621-2630. PubMed ID: 32661602
    [Abstract] [Full Text] [Related]

  • 3. Combination of circulating tumor cells and 18F-FDG PET/CT for precision diagnosis in patients with non-small cell lung cancer.
    Sun M, Lu D, Li X, Wang J, Zhang L, Yang P, Yang Y, Shen J.
    Cancer Med; 2024 Sep 01; 13(18):e70216. PubMed ID: 39302034
    [Abstract] [Full Text] [Related]

  • 4. Prognostic Significance of FDG Uptake of Bone Marrow on PET/CT in Patients With Non-Small-Cell Lung Cancer After Curative Surgical Resection.
    Lee JW, Na JO, Kang DY, Lee SY, Lee SM.
    Clin Lung Cancer; 2017 Mar 01; 18(2):198-206. PubMed ID: 27495385
    [Abstract] [Full Text] [Related]

  • 5. An observational study of circulating tumor cells and (18)F-FDG PET uptake in patients with treatment-naive non-small cell lung cancer.
    Nair VS, Keu KV, Luttgen MS, Kolatkar A, Vasanawala M, Kuschner W, Bethel K, Iagaru AH, Hoh C, Shrager JB, Loo BW, Bazhenova L, Nieva J, Gambhir SS, Kuhn P.
    PLoS One; 2013 Mar 01; 8(7):e67733. PubMed ID: 23861795
    [Abstract] [Full Text] [Related]

  • 6. Clinical value of F18-fluorodeoxyglucose positron emission tomography-computed tomography in patients with non-small cell lung cancer after potentially curative surgery: experience with 241 patients.
    Kanzaki R, Higashiyama M, Maeda J, Okami J, Hosoki T, Hasegawa Y, Takami M, Kodama K.
    Interact Cardiovasc Thorac Surg; 2010 Jun 01; 10(6):1009-14. PubMed ID: 20197344
    [Abstract] [Full Text] [Related]

  • 7. The maximum standardized uptake value of fluorodeoxyglucose positron emission tomography of the primary tumour is a good predictor of pathological nodal involvement in clinical N0 non-small-cell lung cancer.
    Miyasaka Y, Suzuki K, Takamochi K, Matsunaga T, Oh S.
    Eur J Cardiothorac Surg; 2013 Jul 01; 44(1):83-7. PubMed ID: 23233074
    [Abstract] [Full Text] [Related]

  • 8. Prognostic value of SUVmax and metabolic tumor volume on 18F-FDG PET/CT in early stage non-small cell lung cancer patients without LN metastasis.
    Yoo IeR, Chung SK, Park HL, Choi WH, Kim YK, Lee KY, Wang YP.
    Biomed Mater Eng; 2014 Jul 01; 24(6):3091-103. PubMed ID: 25227018
    [Abstract] [Full Text] [Related]

  • 9. 18F-FDG PET/CT and circulating tumor cells in treatment-naive patients with non-small-cell lung cancer.
    Zhang F, Wu X, Zhu J, Huang Y, Song X, Jiang L.
    Eur J Nucl Med Mol Imaging; 2021 Sep 01; 48(10):3250-3259. PubMed ID: 33630146
    [Abstract] [Full Text] [Related]

  • 10. Areas of high 18F-FDG uptake on preradiotherapy PET/CT identify preferential sites of local relapse after chemoradiotherapy for non-small cell lung cancer.
    Calais J, Thureau S, Dubray B, Modzelewski R, Thiberville L, Gardin I, Vera P.
    J Nucl Med; 2015 Feb 01; 56(2):196-203. PubMed ID: 25572091
    [Abstract] [Full Text] [Related]

  • 11. Timing of fluorodeoxyglucose positron emission tomography maximum standardized uptake value for diagnosis of local recurrence of non-small cell lung cancer after stereotactic body radiation therapy.
    Tan D, Gill S, Loh N.
    Cancer Med; 2020 Oct 01; 9(20):7469-7476. PubMed ID: 32846054
    [Abstract] [Full Text] [Related]

  • 12. 18F-FDG uptake as a biologic prognostic factor for recurrence in patients with surgically resected non-small cell lung cancer.
    Higashi K, Ueda Y, Arisaka Y, Sakuma T, Nambu Y, Oguchi M, Seki H, Taki S, Tonami H, Yamamoto I.
    J Nucl Med; 2002 Jan 01; 43(1):39-45. PubMed ID: 11801701
    [Abstract] [Full Text] [Related]

  • 13. Prognostic value of preoperative positron emission tomography in resected stage I non-small cell lung cancer.
    Goodgame B, Pillot GA, Yang Z, Shriki J, Meyers BF, Zoole J, Gao F, Dehdashti F, Patterson A, Siegel BA, Govindan R.
    J Thorac Oncol; 2008 Feb 01; 3(2):130-4. PubMed ID: 18303432
    [Abstract] [Full Text] [Related]

  • 14. Prognostic significance of volume-based 18F-FDG PET/CT parameter in patients with surgically resected non-small cell lung cancer. Comparison with immunohistochemical biomarkers.
    Lee JY, Choi JY, Heo JH, Han J, Jang SJ, Kim K, Kim J, Shim YM, Kim BT.
    Nuklearmedizin; 2016 Feb 01; 55(1):7-14. PubMed ID: 26875430
    [Abstract] [Full Text] [Related]

  • 15. Clinical Predictors of Nodal Metastases in Peripherally Clinical T1a N0 Non-Small Cell Lung Cancer.
    Ghaly G, Rahouma M, Kamel MK, Nasar A, Harrison S, Nguyen AB, Port J, Stiles BM, Altorki NK, Lee PC.
    Ann Thorac Surg; 2017 Oct 01; 104(4):1153-1158. PubMed ID: 28551047
    [Abstract] [Full Text] [Related]

  • 16. Risk factors associated with recurrence of surgically resected node-positive non-small cell lung cancer.
    Ohtaki Y, Shimizu K, Kaira K, Nagashima T, Obayashi K, Nakazawa S, Kakegawa S, Igai H, Kamiyoshihara M, Nishiyama M, Takeyoshi I.
    Surg Today; 2016 Oct 01; 46(10):1196-208. PubMed ID: 26782692
    [Abstract] [Full Text] [Related]

  • 17. New positron emission tomography derived parameters as predictive factors for recurrence in resected stage I non-small cell lung cancer.
    Melloni G, Gajate AM, Sestini S, Gallivanone F, Bandiera A, Landoni C, Muriana P, Gianolli L, Zannini P.
    Eur J Surg Oncol; 2013 Nov 01; 39(11):1254-61. PubMed ID: 23948705
    [Abstract] [Full Text] [Related]

  • 18. Glucose Uptake Values in Positron Emission Tomography Are Useful to Predict Survival after Sublobar Resection for Lung Cancer.
    Nakamura H, Saji H, Marushima H, Tagaya R, Kimura H, Takagi M.
    Thorac Cardiovasc Surg; 2017 Mar 01; 65(2):150-157. PubMed ID: 26909560
    [Abstract] [Full Text] [Related]

  • 19. Prognostic value of pre-operative glucose-corrected maximum standardized uptake value in patients with non-small cell lung cancer after complete surgical resection and 5-year follow-up.
    Konings R, van Gool MH, Bard MP, Zwijnenburg A, Titulaer BM, Aukema TS, Valdés Olmos RA, Sikorska K, Klomp HM, Rijna H.
    Ann Nucl Med; 2016 Jun 01; 30(5):362-8. PubMed ID: 26961089
    [Abstract] [Full Text] [Related]

  • 20. FDG Uptake on Positron Emission Tomography Correlates with Survival and Time to Recurrence in Patients with Stage I Non-Small-Cell Lung Cancer.
    Kwon W, Howard BA, Herndon JE, Patz EF.
    J Thorac Oncol; 2015 Jun 01; 10(6):897-902. PubMed ID: 25811445
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 20.